Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Bookmark and Share
Published: 28 Sep 2019
Views: 528
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Prof Solange Peters presents data during a press conference at the 2019 ESMO congress from the CheckMate-227 trial.

This was a trial looking at the two immunotherapy drug combination of nivolumab plus ipilimumab as treatment for a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.

Watch Dr Marina Garassino's comment here.

Watch Dr Marina Garassino's interview with ecancer here

Read more about the study here.